前列腺癌大分割放疗的长期经济价值:随机试验二次分析
该研究基于随机试验患者数据,比较常规IMRT(CIMRT,75.6 Gy/42次/8.4周)与剂量递增中度大分割IMRT(HIMRT,72 Gy/30次/6周)的长期成本。HIMRT加毒性管理总成本为22,957美元,较CIMRT的30,241美元节省7,000美元,且无使CIMRT更便宜的阈值。
要点
- HIMRT较CIMRT节省7,000美元,机构成本验证节省6,000美元
- 毒性管理仅占平均总成本<10%,但高级别肠和泌尿毒性并存时可达26%
- 无任何阈值使CIMRT成为成本更低的方案
核心结论
- HIMRT治疗前列腺癌比CIMRT更具成本效益,即使计入晚期放疗毒性管理成本。
研究设计与样本
- 基于随机试验患者数据的成本最小化分析,比较CIMRT(75.6 Gy/42次/8.4周)与HIMRT(72 Gy/30次/6周)。
- 决策树模型使用中位随访6年的患者水平数据模拟最大晚期肠道和泌尿毒性概率。
- 成本从医疗保健视角按2014年全国报销费率估算,并以机构成本验证。
主要发现
- HIMRT加毒性管理成本为22,957美元,CIMRT为30,241美元,节省7,000美元。
- CIMRT是贡献总成本的5个最具影响力情景中的共同因素。
- 仅伴2-3级肠道或2-3级泌尿毒性患者中,毒性管理占总成本<10%。
- 同时伴高级别肠道和泌尿毒性患者中,毒性管理占总成本高达26%。
- 机构成本验证HIMRT节省6,000美元,且无阈值使CIMRT成本更低。
关键数值与推荐
- CIMRT方案:75.6 Gy分42次,历时8.4周。
- HIMRT方案:72 Gy分30次,历时6周。
- HIMRT加毒性管理成本22,957美元,CIMRT为30,241美元,节省7,000美元。
- 毒性管理占平均总成本<10%(2-3级肠道或泌尿毒性)至高达26%(高级别肠道和泌尿毒性并存)。
临床怎么用
- 优先选用HIMRT可缩短疗程并降低总体医疗成本。
- 晚期毒性管理成本不应成为选择CIMRT的理由。
局限性
- 成本基于2014年全国报销费率和机构成本,可能不适用于其他医疗体系。
- 决策树模型基于试验概率,敏感性分析评估了模型不确定性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Moderately hypofractionated intensity modulated radiation therapy (HIMRT) for prostate cancer shortens the treatment course while providing outcomes comparable with those of conventional intensity modulated radiation therapy (CIMRT). To determine the long-term economic value of HIMRT, including the costs of managing long-term radiation toxicities, a cost minimization analysis compared CIMRT with dose-escalated HIMRT using patient-level data from a randomized trial. METHODS AND MATERIALS: Men with localized prostate cancer were randomized to CIMRT (75.6 Gy in 42 fractions over 8.4 weeks) or HIMRT (72 Gy in 30 fractions over 6 weeks). A decision tree modeled trial probabilities of maximum late bowel and urinary toxicities using patient-level data with a median follow-up of 6 years. Costs were estimated from the healthcare perspective using the 2014 national reimbursement rates for services received. Patient-level institutional costs, adjusted to 2014 dollars, verified reimbursements. A sensitivity analysis assessed model uncertainty. RESULTS: The cost for HIMRT and toxicity management was $22,957, saving $7,000 compared with CIMRT ($30,241). CIMRT was the common factor among the 5 most influential scenarios that contributed to total costs. Toxicity represented a small part (<10%) of the average total cost for patients with either grade 2-3 bowel toxicity or grade 2-3 urinary toxicity. However, toxicity management reached up to 26% of the total cost for patients with both high-grade bowel and urinary toxicities. There was no threshold at which CIMRT became the less costly regimen. Institutional costs confirmed the economic value of HIMRT ($6,000 in savings). CONCLUSIONS: HIMRT is more cost-efficient than CIMRT for treating prostate cancer, even when taking into account the costs related to late radiation toxicities. HIMRT enhances the value of prostate radiation when compared with CIMRT.
引用
- Voong KR, Lal LS, Kuban DA, et al. Long-term economic value of hypofractionated prostate radiation: Secondary analysis of a randomized trial. Adv Radiat Oncol. 2017. PMID: 29114589. doi:10.1016/j.adro.2017.07.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。